The objective of this project is the non-invasive prenatal detection of placenta-limited aneuploidies, in patients whose fetuses have a intrauterine growth restriction below 3rd percentile, in parallel with an amniocentesis.

This study will allow the chromosomal study of the placenta in pregnant women whose genetic prenatal diagnosis, made by amniocentesis, does not allow exploring the placental causes of fetal RCIU.

Placental chromosomal aneuploidies will be detected by high-throughput whole genome sequencing of non-cellular DNA present in maternal plasma during pregnancy.

The study of the cfDNA will be carried out from a blood sample with the automated solution VERISEQ NIPT (Illumina) using the software illumina VeriSeq v2, allowing the detection of all chromosomal abnormalities.

Inclusion Criteria:

• over 18 years old,
• treated in the DDIANE fetal medicine centre at the Bordeaux University Hospital,
• having a fetus with IUGR diagnosis below the 3rd percentile (after reference medical ultrasound),
• from 16 weeks of amenorrhea or more,
• accepting an Invasive Prenatal Diagnosis by amniocentesis with array comparative genomic hybridization

Exclusion Criteria:

Childbearing women who:

• do not accept a non-invasive prenatal diagnosis (amniocentesis)
• have a fetus with non-isolated IUGR (associated with other ultrasound signs)
• do not consent to participate in the research protocol

having a fetus with IUGR diagnosis below the 3rd percentile (after reference medical ultrasound)

Patient having a fetus with IUGR diagnosis below the 3rd percentile (after reference medical ultrasound)